Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non‑squamous non-small‑cell lung cancer

Masago,Katsuhiro; Fujimoto,Daichi; Fujita,Shiro; Hata,Akito; Kaji,Reiko; Ohtsuka,Kyoko; Okuda,Chiyuki; Takeshita,Jumpei; Katakami,Nobuyuki

doi:10.3892/mco.2014.457

Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non‑squamous non-small‑cell lung cancer

Authors:
- Katsuhiro Masago
- Daichi Fujimoto
- Shiro Fujita
- Akito Hata
- Reiko Kaji
- Kyoko Ohtsuka
- Chiyuki Okuda
- Jumpei Takeshita
- Nobuyuki Katakami
View Affiliations

Affiliations: Division of Integrated Oncology, Institute of Biomedical Research and Innovation Hospital, Kobe, Hyogo 650‑0047, Japan, Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Hyogo 650-0047, Japan
Published online on: November 19, 2014 https://doi.org/10.3892/mco.2014.457
Pages: 415-419

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant pleural effusion (MPE) is a common complication of lung cancer with devastating consequences. Since vascular endothelial growth factor (VEGF) has been implicated in MPE, we hypothesized that bevacizumab, an anti‑VEGF antibody, may be effective against MPE in patients with non‑small‑cell lung cancer (NSCLC). We analysed the records of 21 patients treated for NSCLC‑associated MPE between February, 2010 and August, 2013 who consequently underwent bevacizumab combination chemotherapy at the Institute of Biomedical Research and Innovation Hospital. The results were retrospectively analysed using case records and radiographic imaging records. Three patients exhibited complete response of the pleural effusion to bevacizumab treatment, 8 patients achieved a partial response (PR) and 6 patients showed no response. When efficacy was assessed by the response of the measurable primary or metastatic lesions to the treatment, 5 patients achieved a PR, 13 patients had stable disease and 3 patients exhibited progressive disease. The response rate (RR) of the pleural effusion to the antibody treatment was 71.4% and the overall rr of measurable lesions was 23.8%. The median time‑to‑response for pleural effusion was 132 days. In conclusion, this study demonstrated a high rR to bevacizumab combination therapy for the MPE associated with non‑squamous NSCLC. Therefore, bevacizumab therapy may be considered a therapeutic option for patients with non‑squamous NSCLC who develop MPE.

View Figures

View References

1	Anderson CB, Philpott GW and Ferguson TB: The treatment of malignant pleural effusions. Cancer. 33:916–922. 1974. View Article : Google Scholar : PubMed/NCBI
2	Memon A and Zawadzki ZA: Malignant effusions: diagnostic evaluation and therapeutic strategy. Curr Probl Cancer. 5:1–30. 1981. View Article : Google Scholar : PubMed/NCBI
3	Thomas JM and Musani AI: Malignant pleural effusions: a review. Clin Chest Med. 34:459–471. 2013. View Article : Google Scholar : PubMed/NCBI
4	Zebrowski BK, Yano S, Liu W, et al: Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res. 5:3364–3368. 1999.PubMed/NCBI
5	Brown LF, Detmar M, Claffey K, et al: Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS. 79:233–269. 1997.PubMed/NCBI
6	Takahama M, Tsutsumi M, Tsujiuchi T, et al: Enhanced expression of Tie 2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas. Clin Cancer Res. 5:2506–2510. 1999.PubMed/NCBI
7	Ferrara N: Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol. 237:1–30. 1999.PubMed/NCBI
8	Bertino EM and Otterson GA: Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer. Lung Cancer. 70:233–246. 2010. View Article : Google Scholar : PubMed/NCBI
9	Wang Y, Fei D, Vanderlaan M and Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 7:335–345. 2004. View Article : Google Scholar : PubMed/NCBI
10	Ribeiro SC, Vargas FS, Antonangelo L, et al: Monoclonal anti-vascular endothelial growth factor antibody reduces fluid volumein an experimental model of inflammatory pleural effusion. Respirology. 14:1188–1193. 2009. View Article : Google Scholar : PubMed/NCBI
11	Pichelmayer O, Zielinski C and Raderer M: Response of a nonmalignant pleural effusion to bevacizumab. N Engl J Med. 353:740–741. 2005. View Article : Google Scholar : PubMed/NCBI
12	Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
13	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
14	Fujita A, Takabatake H, Tagaki S and Sekine K: Combination chemotherapy in patients with malignant pleural effusions from non-small cell lung cancer: cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony-stimulating factor support. Chest. 119:340–343. 2001. View Article : Google Scholar : PubMed/NCBI
15	Goldstraw P, Crowley J, Chansky K, et al International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007. View Article : Google Scholar : PubMed/NCBI
16	Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 22:2184–2191. 2004. View Article : Google Scholar : PubMed/NCBI
17	Musani AI: Treatment options for malignant pleural effusion. Curr Opin Pulm Med. 15:380–387. 2009. View Article : Google Scholar : PubMed/NCBI
18	Kitamura K, Kubota K, Ando M, et al: Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion. Cancer Chemother Pharmacol. 71:457–461. 2012. View Article : Google Scholar : PubMed/NCBI
19	Du N, Li X, Li F, et al: Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion. Oncol Rep. 29:2332–2340. 2013.PubMed/NCBI
20	Verheul HM, Hoekman K, Jorna AS, Smit EF and Pinedo HM: Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist. 1:45–50. 2000. View Article : Google Scholar
21	Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto Y, Bando H and Sone S: Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother. 48:396–400. 1999. View Article : Google Scholar : PubMed/NCBI
22	Yano S, Shinohara H, Herbst RS, et al: Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol. 157:1893–1903. 2000. View Article : Google Scholar : PubMed/NCBI
23	Cheng D, Rodriguez RM, Perkett EA, et al: Vascular endothelial growth factor in pleural fluid. Chest. 116:760–765. 1999. View Article : Google Scholar : PubMed/NCBI
24	Hsu IL, Su WC, Yan JJ, Chang JM and Lai WW: Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control. Lung Cancer. 65:371–376. 2009. View Article : Google Scholar : PubMed/NCBI
25	Yano S, Herbst RS, Shinohara H, et al: Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res. 6:957–965. 2000.PubMed/NCBI
26	Mesiano S, Ferrara N and Jaffe RB: Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol. 153:1249–1256. 1998. View Article : Google Scholar : PubMed/NCBI
27	Ma X, Yao Y, Yuan D, et al: Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PLoS One. 7:e534492012. View Article : Google Scholar : PubMed/NCBI